Effectiveness and safety of standard and reduced dosages of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the SNDS French nationwide claims database
ConclusionThis nationwide study of new anticoagulant users for NVAF shows a better benefit-risk of dabigatran standard and reduced dosages compared to rivaroxaban in real-world setting.
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Databases & Libraries | France Health | Heart | Pradaxa | Stroke | Study